SAGE-718 Showing Potential to Aid Patients’ Thinking, Memory in Trial
Early results from the Phase 2 clinical trial of oral SAGE-718 showed the investigative therapy’s use was associated with cognitive gains in people with mild impairment due to Parkinson’s disease. These findings were presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s…